Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-05-2011 | Article

Impaired antibody response to conjugated meningococcal serogroup C vaccine in asplenic patients

Authors: A. Meerveld-Eggink, O. de Weerdt, R. M. de Voer, G. A. M. Berbers, H. van Velzen-Blad, B. J. Vlaminckx, D. H. Biesma, G. T. Rijkers

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 5/2011

Abstract

The purpose of this study was to determine the quantity and quality of antibodies against the meningococcal serogroup C (MenC) conjugated vaccine in asplenic patients. In 116 asplenic patients, antibody concentrations (IgG) were measured against meningococcal serogroup C before and after immunisation. Of MenC-specific IgG, both antibody avidity and subclasses of IgG1 and IgG2 were determined. The mean MenC IgG concentration rose from 0.16 μg/mL prior to vaccination to 3.69 μg/mL 3 weeks post-vaccination, with 67% of patients reaching the threshold of ≥2.0 μg/mL. The mean IgG concentration at 35 weeks post-vaccination was 3.10 μg/mL. IgG2 concentrations increased more than IgG1. Marginal avidity maturation was seen. Hypo-responders to the first MenC vaccine (IgG anti-MenC ≤ 2.0 μg/mL) were offered a booster dose. After revaccination, 59% reached the chosen IgG threshold. The IgG concentration rose from 0.29 to 1.12 μg/mL, with an increase in the IgG1/IgG2 ratio. Avidity indices remained below 33%. In asplenic patients, the quantity and quality of antibodies produced after one dose of conjugated MenC vaccination is lower than that observed in previous studies in healthy adults. Booster vaccination does, indeed, lead to a rise in IgG geometric mean concentrations (GMCs), but does not lead to higher avidity of antibodies.

[No authors listed] (1997) Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 46(RR-8):1–24

[No authors listed] (1996) Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Working Party of the British Committee for Standards in Haematology Clinical Haematology Task Force. BMJ 312(7028):430–434

Davies JM, Barnes R, Milligan D; British Committee for Standards in Haematology. Working Party of the Haematology/Oncology Task Force (2002) Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Clin Med 2(5):440–443PubMed

Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC) (2005) Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 54(RR-7):1–21PubMed

Granoff DM, Harris SL (2004) Protective activity of group C anticapsular antibodies elicited in two-year-olds by an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 23(6):490–497PubMedCrossRef

de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A (2006) Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 25(1):79–80PubMedCrossRef

Giebink GS, Foker JE, Kim Y, Schiffman G (1980) Serum antibody and opsonic responses to vaccination with pneumococcal capsular polysaccharide in normal and splenectomized children. J Infect Dis 141(3):404–412PubMedCrossRef

Sullivan JL, Ochs HD, Schiffman G, Hammerschlag MR, Miser J, Vichinsky E et al (1978) Immune response after splenectomy. Lancet 1(8057):178–181PubMedCrossRef

Eigenberger K, Sillaber C, Greitbauer M, Herkner H, Wolf H, Graninger W et al (2007) Antibody responses to pneumococcal and hemophilus vaccinations in splenectomized patients with hematological malignancies or trauma. Wien Klin Wochenschr 119(7–8):228–234PubMedCrossRef

10.

Smets F, Bourgois A, Vermylen C, Brichard B, Slacmuylders P, Leyman S et al (2007) Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine. Vaccine 25(29):5278–5282PubMedCrossRef

11.

Melles DC, de Marie S (2004) Prevention of infections in hyposplenic and asplenic patients: an update. Neth J Med 62(2):45–52PubMed

12.

Davidson RN, Wall RA (2001) Prevention and management of infections in patients without a spleen. Clin Microbiol Infect 7(12):657–660PubMedCrossRef

13.

Wuorimaa T, Dagan R, Väkeväinen M, Bailleux F, Haikala R, Yaich M et al (2001) Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J Infect Dis 184(9):1211–1215PubMedCrossRef

14.

Harris SL, Tsao H, Ashton L, Goldblatt D, Fernsten P (2007) Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays. Clin Vaccine Immunol 14(4):397–403PubMedCrossRef

15.

Goldblatt D, Vaz AR, Miller E (1998) Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 177(4):1112–1115PubMedCrossRef

16.

Kelly DF, Pollard AJ, Moxon ER (2005) Immunological memory: the role of B cells in long-term protection against invasive bacterial pathogens. JAMA 294(23):3019–3023PubMedCrossRef

17.

Balmer P, Borrow R (2004) Serologic correlates of protection for evaluating the response to meningococcal vaccines. Expert Rev Vaccines 3(1):77–87PubMedCrossRef

18.

Schlesinger Y, Granoff DM (1992) Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 267(11):1489–1494PubMedCrossRef

19.

Meerveld-Eggink A, de Weerdt O, Rijkers GT, van Velzen-Blad H, Biesma DH (2008) Vaccination coverage and awareness of infectious risks in patients with an absent or dysfunctional spleen in the Netherlands. Vaccine 26(52):6975–6979PubMedCrossRef

20.

de Voer RM, Schepp RM, Versteegh FG, van der Klis FR, Berbers GA (2009) Simultaneous detection of Haemophilus influenzae type b polysaccharide-specific antibodies and Neisseria meningitidis serogroup A, C, Y, and W-135 polysaccharide-specific antibodies in a fluorescent-bead-based multiplex immunoassay. Clin Vaccine Immunol 16(3):433–436PubMedCrossRef

21.

de Voer RM, van der Klis FR, Engels CW, Schepp RM, van de Kassteele J, Sanders EA et al (2009) Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults. Vaccine 27(50):6974–6982PubMedCrossRef

22.

Lal G, Balmer P, Joseph H, Dawson M, Borrow R (2004) Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135. Clin Diagn Lab Immunol 11(2):272–279PubMed

23.

de Voer RM, van der Klis FR, Engels CW, Rijkers GT, Sanders EA, Berbers GA (2008) Development of a fluorescent-bead-based multiplex immunoassay to determine immunoglobulin G subclass responses to Neisseria meningitidis serogroup A and C polysaccharides. Clin Vaccine Immunol 15(8):1188–1193PubMedCrossRef

24.

Holder PK, Maslanka SE, Pais LB, Dykes J, Plikaytis BD, Carlone GM (1995) Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992. Clin Diagn Lab Immunol 2(2):132–137PubMed

25.

Joseph H, Balmer P, Bybel M, Papa T, Ryall R, Borrow R (2004) Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera. Clin Diagn Lab Immunol 11(1):1–5PubMed

26.

Anttila M, Eskola J, Ahman H, Käyhty H (1998) Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 177(6):1614–1621PubMedCrossRef

27.

Zonneveld-Huijssoon E, Ronaghy A, Van Rossum MA, Rijkers GT, van der Klis FR, Sanders EA et al (2007) Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritis. Arthritis Rheum 56(2):639–646PubMedCrossRef

28.

Burrage M, Robinson A, Borrow R, Andrews N, Southern J, Findlow J et al (2002) Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun 70(9):4946–4954PubMedCrossRef

29.

Richmond P, Goldblatt D, Fusco PC, Fusco JD, Heron I, Clark S et al (1999) Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 18(7–8):641–646PubMedCrossRef

30.

Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, Morris R et al (2001) Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 183(1):160–163PubMedCrossRef

31.

Balmer P, Falconer M, McDonald P, Andrews N, Fuller E, Riley C et al (2004) Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals. Infect Immun 72(1):332–337PubMedCrossRef

32.

Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S et al (2009) The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50–80 years. Clin Infect Dis 49(9):1318–1325PubMedCrossRef

33.

Blanchard Rohner G, Snape MD, Kelly DF, John T, Morant A, Yu LM et al (2008) The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. J Immunol 180(4):2165–2173PubMed

34.

Southern J, Deane S, Ashton L, Borrow R, Goldblatt D, Andrews N et al (2004) Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin Diagn Lab Immunol 11(6):1100–1104PubMed

35.

Goldblatt D, Borrow R, Miller E (2002) Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. J Infect Dis 185(3):397–400PubMedCrossRef

36.

Hutchins WA, Carlone GM, Westerink MA (1999) Elderly immune response to a TI-2 antigen: heavy and light chain use and bactericidal activity to Neisseria meningitidis serogroup C polysaccharide. J Infect Dis 179(6):1433–1440PubMedCrossRef

37.

Findlow H, Southern J, Mabey L, Balmer P, Heyderman RS, Auckland C et al (2006) Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccine. Clin Vaccine Immunol 13(4):507–510PubMedCrossRef

38.

Mäkelä O, Mattila P, Rautonen N, Seppälä I, Eskola J, Käyhty H (1987) Isotype concentrations of human antibodies to Haemophilus influenzae type b polysaccharide (Hib) in young adults immunized with the polysaccharide as such or conjugated to a protein (diphtheria toxoid). J Immunol 139(6):1999–2004PubMed

Title: Impaired antibody response to conjugated meningococcal serogroup C vaccine in asplenic patients
Authors: A. Meerveld-Eggink
O. de Weerdt
R. M. de Voer
G. A. M. Berbers
H. van Velzen-Blad
B. J. Vlaminckx
D. H. Biesma
G. T. Rijkers
Publication date: 01-05-2011
Publisher: Springer-Verlag
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 5/2011
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-010-1129-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2011

Time to revise the paradigm of hantavirus syndromes? Hantavirus pulmonary syndrome caused by European hantavirus

Identification of gentian violet concentration that does not stain oral mucosa, possesses anti-candidal activity and is well tolerated

Impact of administration of vancomycin or linezolid to critically ill patients with impaired renal function

Pneumocystosis: a network survey in the Paris area 2003–2008

Serratia infections in a general hospital: characteristics and outcomes

Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient—a review of the literature

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials